Investor Presentaiton
|||
Operations
and performance
Economic-financial results
GRI 201-1
Net Revenue
In 2021, adjusted net revenue totaled R$ 5,997,4 million, an increase of 35.9% com-
pared to 2020. This result is due to an organic growth of 14.2% and acquisitions
made during the period.
R$ thousand
Net Revenue
Adjusted net revenue*
2021
6,218,759
5,997,425
2020
4,413,421
4,413,421
Var.
2021/2020
40.9%
35.9%
In 2021, the adjusted net revenue of the distribution channel for hospitals and clin-
ics totaled R$ 5,109.6 million, an increase of 30.5% compared to 2020. The annual
growth is mainly due to the higher sales volume of high-cost drugs and vaccines.
The first two quarters saw stronger sales related to Covid-19 and a slowdown in
the third and fourth quarters due to the moment of the pandemic and the highly
stocked hospitals. In the second half of 2021, there was also a brief resumption of
elective procedures, but still below pre-pandemic levels. Organic growth was 12.5%
in 2021 compared to 2020.
In the distribution channel for hospitals and clinics in 2021, 58.5% of net revenue
refers to high-cost drugs, materials (including Cremer) represented by 19.0%, other
medicines 15.8%, and vaccines 6.7%.
Economic-financial
results
* Excludes the positive effect of DIFAL (ICMS rate differential) of R$ 17.7 million in
4021 and R$ 221.3 million in 2021.
Net revenue per channel
% of net revenue 2021
Distribution to hospitals and clinics
5.4%
Other materials
R$ thousand
2021
2020
Var.
2021/2020
13.6%
Manufacture
(Cremer)
Hospitals and clinics*
5,109,644
3,915,015
30.5%
Laboratories
220,260
135,174
62.9%
Retail
583,787
315,424
85.1%
15.8%
Services
83,734
47,808
75.1%
Others
Medicine
Total
5,997,425
4,413,421
35.9%
* Excludes the positive effect of DIFAL (ICMS rate differential) of R$ 221.3 million in 2021.
42
viveo
Sustainability Report 2021
6.7%
Vaccine
and PPE
58.5%
High-cost drugsView entire presentation